文献速递脑血管病

老年急性缺血性卒中患者替奈普酶与阿替普酶的安全性、功能残疾、医疗利用及生活质量结局:AcT试验二次分析

Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial.
PubMed 文献 · Stroke · 2025-03-24

AcT试验二次分析纳入1577例急性缺血性卒中患者,比较<80岁与≥80岁患者的功能残疾、安全性、医疗利用及生活质量结局,并评估替奈普酶与阿替普酶的效应差异。结果显示≥80岁组功能结局更差、死亡率更高、生活质量更低,但症状性颅内出血率相似;溶栓药物类型未改变年龄与主要临床结局的关联。

要点

  • ≥80岁患者较<80岁患者功能结局优良率、恢复至基线状态率显著更低,死亡率更高,生活质量更差。
  • 症状性颅内出血率<80岁组3.5% vs ≥80岁组3.1%,两组无差异。
  • 替奈普酶与阿替普酶对年龄与主要临床结局的关联无修饰作用(交互作用P=0.22)。

核心结论

  • 与阿替普酶相似,高龄与替奈普酶治疗后更差的功能结局相关。
  • 年龄<80岁与≥80岁患者血管造影及出血结局相似。

研究设计与样本

  • AcT试验(阿替普酶对比替奈普酶治疗急性缺血性卒中)的二次分析,为实用性、注册链接的3期随机对照试验。
  • 共纳入1577例患者,<80岁1034例(65.6%;替奈普酶520例,阿替普酶514例),≥80岁543例(34.4%;替奈普酶286例,阿替普酶257例)。
  • 采用混合效应泊松回归评估年龄与结局的关联及溶栓药物类型(替奈普酶 vs 阿替普酶)对关联的修饰作用,校正性别和基线卒中严重程度。

主要发现

  • ≥80岁组较<80岁组功能结局优良率、恢复至基线状态率显著更低,死亡率更高,生活质量结局更差。
  • 症状性颅内出血率<80岁组3.5% vs ≥80岁组3.1%,两组无差异。
  • 两组住院时间相似,但≥80岁组血管内治疗利用率显著更低。
  • 溶栓药物类型(替奈普酶 vs 阿替普酶)未修饰年龄与主要临床结局的关联(交互作用P=0.22)。

关键数值与推荐

  • 功能残疾采用90天改良Rankin量表评估。
  • 安全性指标包括24小时症状性颅内出血和90天死亡率。
  • 医疗利用指标包括出院去向、住院时间和取栓率。
  • 生活质量采用EQ-5D-5L量表评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older age has been associated with overall poorer outcomes in acute ischemic stroke. We compared (1) outcomes in various health-related domains among patients <80 years and ≥80 years presenting with acute ischemic stroke and (2) whether outcomes differ between intravenous TNK (tenecteplase) versus alteplase. METHODS: Data are from patients included in AcT (Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke), a pragmatic, registry-linked, phase 3 randomized controlled trial comparing TNK with alteplase. Outcomes included functional disability (per 90-day modified Rankin Scale), safety (24-hour symptomatic intracerebral hemorrhage, 90-day mortality rates), health care utilization (discharge destination, length of stay, thrombectomy rate), and quality of life measures (EQ-5D-5L [EuroQol 5-Dimension 5-Level Scale]). With an a priori plan, patients aged <80 years were compared with those ≥80 years at symptom onset. Mixed effects Poisson regression was used to assess (1) the association of age with outcomes and (2) if these associations were modified by thrombolytic administered (TNK versus alteplase), after adjusting for sex, and baseline stroke severity. RESULTS: Of the 1577 patients, 1034 (65.6%; 520: TNK and 514: alteplase) were <80 years and 543 (34.4%; 286: TNK and 257: alteplase) were ≥80 years of age. Baseline characteristics in the 2 groups were similar except for sex 40% female in <80 years group versus 62.8% female in ≥80 years. There was no difference in rates of symptomatic intracranial hemorrhage (3.5% versus 3.1%). Patients in the ≥80 years group had significantly lower rates of excellent functional outcome, return to baseline status, higher mortality, and lower quality-of-life outcomes as compared with the <80 years group. Length of hospital stay was similar between the 2 groups but, patients in the ≥80 years age group had significantly lower rates of endovascular treatment utilization. Type of thrombolytic agent (TNK versus alteplase) did not modify the association between age and primary clinical outcome (Pinteraction=0.22). CONCLUSIONS: Similar to alteplase, increasing age was associated with poorer functional outcomes with TNK. Rates of angiographic and bleeding outcomes were similar between patients <80 and ≥80 years. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03889249.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Singh N, Bala F, Ademola A, et al. Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial. Stroke. 2025. PMID: 40123483. doi:10.1161/STROKEAHA.124.049512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。